Shanlin Tong, raised in Beijing and later residing in Sweden, pursued a BSc and MSc in Biomedicine at Karolinska Institutet before attending medical school at the University of Groningen. Currently, he is funded for his PhD by Horizon 2020 Marie Curie ITN at Okkenhaug Lab, Department of Pathology, University of Cambridge. His research focuses on understanding the PI3K signaling pathway's role in B cell malignancies' development, utilizing advanced techniques such as flow cytometry, molecular cloning, single-cell RNA sequencing, BCR sequencing, in vivo animal models, and CRISPR screens. His current work involves understanding the oncogenic role of PI3K kinase and exploring drug candidates to target B cell lymphoma.